Jane Chung - 10 Aug 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Director
Signature
/s/ Daniel Chevallard, as Attorney-in-Fact
Issuer symbol
VIRX
Transactions as of
10 Aug 2022
Net transactions value
$0
Form type
4
Filing time
11 Aug 2022, 18:58:40 UTC
Previous filing
10 Aug 2022
Next filing
07 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 10 Aug 2022 Common Stock 80,000 $3.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth (1/36) of the shares subject to the option shall vest monthly beginning on the one month anniversary of August 10, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.